Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(1.15) per share which beat the analyst consensus estimate of $(1.32) by 12.94 percent. This is a 167.44 percent decrease over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $203.000 million which beat the analyst consensus estimate of $156.094 million by 30.05 percent. This is a 10.57 percent decrease over sales of $227.000 million the same period last year.